Cervical cancer is a humanitarian emergency, with more than 90% of deaths related to this disease occurring in LMICs. Early screening allows precancerous lesions to be eradicated in a very simple way. The MSF Foundation, in collaboration with MSF and Epicentre, has joined an international consortium dedicated to improving cervical cancer screening. Led by the NCI in the United States, this consortium is conducting a wide-ranging study on more than 100,000 women to evaluate a new approach to cervical cancer screening: the  PAVE (Human Papillomavirus and Automated Visual Evaluation) study.  This new approach combines identifying women infected with an oncogenic strain of Human Papilloma Virus (HPV) - at high risk of developing into cancer  - and, among these women with high-risk HPV, using Artificial Intelligence (AI) to help identify those with precancerous lesions that can be treated on the spot The MSF Foundation and its partners will conduct this clinical study in Malawi as part of MSF's program for care of women with cervical cancer at the Queen Elizabeth Hospital and the screening program in Blantyre health centers.